{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:03:24Z","timestamp":1791198204949,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05423-7","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:49:09Z","timestamp":1791197349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reevaluating predictive factors for treatment success in therapy with OnabotulinumtoxinA for iOAB in a real-world study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1888-1470","authenticated-orcid":false,"given":"Sebastian","family":"Nestler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subaidah","family":"Alloussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Gr\u00fcne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Carl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Garm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neisius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"2","key":"5423_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C (2013) OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 64(2):249\u2013256","journal-title":"Eur Urol"},{"issue":"6","key":"5423_CR2","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C, EMBARK Study Group (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189(6):2186\u20132193","journal-title":"J Urol"},{"issue":"19","key":"5423_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","volume":"367","author":"AG Visco","year":"2012","unstructured":"Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Lowder J, Khandwala S, Sirls L, Spino C, Nolen TL, Wallace D, Meikle SF, Pelvic Floor Disorders Network (2012) Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med 367(19):1803\u20131813","journal-title":"N Engl J Med"},{"issue":"1","key":"5423_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00192-020-04423-0","volume":"32","author":"R Hamid","year":"2021","unstructured":"Hamid R, Lorenzo-Gomez MF, Schulte-Baukloh H, Boroujerdi A, Patel A, Farrelly E (2021) OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice. Int Urogynecol J 32(1):65\u201374","journal-title":"Int Urogynecol J"},{"issue":"7","key":"5423_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/SPV.0000000000000914","volume":"27","author":"K McCammon","year":"2021","unstructured":"McCammon K, Gousse A, Kohan A, Glazier D, Gruenenfelder J, Bai Z, Patel A, Hale D (2021) Early and consistent improvements in urinary symptoms and quality of life with OnabotulinumtoxinA in patients with overactive bladder and urinary incontinence: results from a randomized, placebo-controlled, phase IV clinical trial. Female Pelvic Med Reconstr Surg 27(7):450\u2013456","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"10","key":"5423_CR6","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/s11255-025-04508-z","volume":"57","author":"S Nestler","year":"2025","unstructured":"Nestler S, Gr\u00fcne B, Schilchegger L, Neisius A (2025) Adherence to botulinum toxin therapy in female patients with idiopathic overactive bladder: a 48-month real-world observational study. Int Urol Nephrol 57(10):3199\u20133206","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"5423_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.urology.2008.05.033","volume":"72","author":"S Colman","year":"2008","unstructured":"Colman S, Chapple C, Nitti V, Haag-Molkenteller C, Hastedt C, Massow U (2008) Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 72(4):803\u2013807","journal-title":"Urology"},{"issue":"6","key":"5423_CR8","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.euf.2020.06.013","volume":"7","author":"M Abrar","year":"2021","unstructured":"Abrar M, Pindoria N, Malde S, Chancellor M, DeRidder D, Sahai A (2021) Predictors of poor response and adverse events following botulinum toxin A for refractory idiopathic overactive bladder: a systematic review. Eur Urol Focus 7(6):1448\u20131467","journal-title":"Eur Urol Focus"},{"key":"5423_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF00451721","volume":"3","author":"SA Shumaker","year":"1994","unstructured":"Shumaker SA, Wyman JF, Uebersax JS et al (1994) Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Qual Life Res 3:291\u2013306","journal-title":"Qual Life Res"},{"issue":"4","key":"5423_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/nau.70261","volume":"45","author":"MG Hanna","year":"2026","unstructured":"Hanna MG, Shah AM, Li W, Sejdic E, Bradley M, Zuo SW, Artsen AM (2026) Urinary cytokines in predicting intradetrusor OnabotulinumtoxinA response. Neurourol Urodyn 45(4):845\u2013852","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"5423_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147137","volume":"11","author":"SM Hsiao","year":"2016","unstructured":"Hsiao SM, Lin HH, Kuo HC (2016) Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. PLoS ONE 11(1):e0147137","journal-title":"PLoS ONE"},{"key":"5423_CR12","unstructured":"Komesu YM, Amundsen CL, Richter HE, Erickson SW, Ackenbom MF, Andy UU, Sung VW, Albo M, Gregory WT, Paraiso MF, Wallace D; Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. Am J Obstet Gynecol. 2018 Jan;218(1):111.e1\u2013111.e9."},{"issue":"2","key":"5423_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/nau.22948","volume":"36","author":"RK Owen","year":"2017","unstructured":"Owen RK, Abrams KR, Mayne C, Slack M, Tincello DG (2017) Patient factors associated with onabotulinum toxin-A treatment outcome in women with detrusor overactivity. Neurourol Urodyn 36(2):426\u2013431","journal-title":"Neurourol Urodyn"},{"key":"5423_CR14","first-page":"1","volume":"0","author":"A Wang","year":"2026","unstructured":"Wang A, Li R, Sun Y (2026) Letter to the editor on \u201cA novel template for intravesical botulinum toxin injection in patients with idiopathic overactive bladder: a cohort study.\u201d Neurourol Urodyn 0:1\u20132","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"5423_CR15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/nau.25191","volume":"42","author":"M Guirguis Hanna","year":"2023","unstructured":"Guirguis Hanna M, Bradley M, Zyczynski H, Wang L, Giugale L (2023) The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA-A secondary analysis. Neurourol Urodyn 42(6):1238\u20131244","journal-title":"Neurourol Urodyn"},{"issue":"11","key":"5423_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/toxins16110462","volume":"16","author":"H Schulte-Baukloh","year":"2024","unstructured":"Schulte-Baukloh H, Apostolidis A, Weiss C, Schlomm T, Weinberger S, H\u00f6ppner D, Haberecht K, Waskow C, Borgmann H, Neymeyer J, Ralla B (2024) Assessing the use of botulinumtoxinA for hyperactive urinary tract dysfunction a decade after approval: general versus local anesthesia for botulinumtoxinA detrusor injection. Toxins (Basel) 16(11):462","journal-title":"Toxins (Basel)"},{"issue":"10","key":"5423_CR17","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/ijcp.12443","volume":"68","author":"KD Sievert","year":"2014","unstructured":"Sievert KD, Chapple C, Herschorn S, Joshi M, Zhou J, Nardo C, Nitti VW (2014) OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract 68(10):1246\u20131256","journal-title":"Int J Clin Pract"},{"issue":"8","key":"5423_CR18","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/nau.21150","volume":"30","author":"I Makovey","year":"2011","unstructured":"Makovey I, Davis T, Guralnick ML, O\u2019Connor RC (2011) Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability. Neurourol Urodyn 30(8):1538\u20131540","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"5423_CR19","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","volume":"184","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184(6):2416\u20132422","journal-title":"J Urol"},{"issue":"4","key":"5423_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/nau.21021","volume":"30","author":"E Rovner","year":"2011","unstructured":"Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30(4):556\u2013562","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"5423_CR21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1742-1241.2011.02663.x","volume":"65","author":"C Dowson","year":"2011","unstructured":"Dowson C, Sahai A, Watkins J, Dasgupta P, Khan MS (2011) The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. Int J Clin Pract 65(6):698\u2013704","journal-title":"Int J Clin Pract"},{"issue":"7","key":"5423_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/nau.70340","volume":"45","author":"GG Salcedo","year":"2026","unstructured":"Salcedo GG, Galvis JSS, Medina SEM, Mart\u00ednez \u00c1G (2026) A novel template for intravesical botulinum toxin injection in patients with idiopathic overactive bladder: a cohort study. Neurourol Urodyn 45(7):1251\u20131257","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"5423_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad332","volume":"10","author":"MP Bilsen","year":"2023","unstructured":"Bilsen MP, Jongeneel RMH, Schneeberger C, Platteel TN, van Nieuwkoop C, Mody L, Caterino JM, Geerlings SE, K\u00f6ves B, Wagenlehner F, Conroy SP, Visser LG, Lambregts MMC (2023) Definitions of urinary tract infection in current research: a systematic review. Open Forum Infect Dis 10(7):ofad332","journal-title":"Open Forum Infect Dis"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05423-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:49:10Z","timestamp":1791197350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05423-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":23,"alternative-id":["5423"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05423-7","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"13 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective character of the study, ethical approval was not necessary. The procedures used in this study adhere to the tenets of the Declaration of Helsinki\n                      .","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate (include appropriate statements)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}